A Study to Evaluate the Distribution of Botulinum Neurotoxin Type A Administered as Intradermal Injections, Comparing Different Doses, Concentrations, and Delivery Methods

June 21, 2023 updated by: Merz Pharmaceuticals GmbH

A Phase 1 Single-center Study to Evaluate the Distribution of NT 201 Administered as Intradermal Injections, Comparing Different Doses, Concentrations, and Delivery Methods

The purpose of this study is to evaluate the distribution of IncobotulinumtoxinA (Xeomin) in healthy subjects at different volumes, concentrations and doses when administered intradermally and subcutaneously using different delivery methods (conventional needle and microneedles).

Study Overview

Status

Completed

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

40

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Hamburg, Germany, 20095
        • Merz Investigational Site #0490385

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 45 years (Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Healthy male or female subject aged 18 to 45 years with body mass index (BMI) 19.0 to 27.0 kg/m².
  • Subject with the distance not less than 45 cm between the spinous process of the 7th cervical vertebra (C7) and the 4th lumbar vertebra (L4).
  • Healthy skin at test area (forehead and back).
  • Fitzpatrick skin type I to IV.
  • Displaying uniform sweating activity (i.e., symmetrical sweating pattern with enough sweat and without anhidrotic regions) on the forehead area as assessed with Minor's starch iodine test under standardized sweating conditions.

Exclusion Criteria:

  • Any chronic pain conditions or presence of acute pain of any origin and intensity.
  • Dermal treatment of the forehead (e.g., light resurfacing, dermabrasions) within the last 12 months before Screening, during the screening period, and/or at Baseline.
  • Any type of filler in the treatment area on the facial region within the last 12 months before Screening, during the screening period, and/or atBaseline; regardless of time for any type of implant and/or surgery in the treatment area on facial region.
  • Any type of surgery in the treatment area of the back within the last 12 months before Screening, during the screening period, and/or at Baseline.
  • Treatment with anticholinergics within the last 14 days before Screening, during the screening period, and/or at Baseline.
  • Treatment with analgesics (e.g., non steroidal anti inflammatory drugs, except acetylsalicylic acid, ibuprofen, and paracetamol) within the last 10 days before Screening, during the screening period, and/or prior to pain assessment at Baseline.
  • Treatment with paracetamol, ibuprofen, or acetylsalicylic acid within three days prior to pain assessment at Baseline.
  • Subjects with excessive sweating or previously diagnosed with hyperhidrosis.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: LMRC (left with micro-/right with conv- needle)
Intradermal injections using different delivery methods (conventional needle and microneedles)
Other Names:
  • Xeomin
  • Botulinum toxin type A (150 kiloDalton), free from complexing proteins
Experimental: RMLC (right with micro-/left with conv- needle)
Intradermal injections using different delivery methods (conventional needle and microneedles)
Other Names:
  • Xeomin
  • Botulinum toxin type A (150 kiloDalton), free from complexing proteins
Experimental: LCRM (left with conv-/ right with micro-needles)
Intradermal injections using different delivery methods (conventional needle and microneedles)
Other Names:
  • Xeomin
  • Botulinum toxin type A (150 kiloDalton), free from complexing proteins
Experimental: RCLM (right with conv-/left with micro-needles)
Intradermal injections using different delivery methods (conventional needle and microneedles)
Other Names:
  • Xeomin
  • Botulinum toxin type A (150 kiloDalton), free from complexing proteins

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Area of anhidrosis on contralateral points of the forehead four weeks after intradermal injections of NT 201 with fixed dose and volume, using different delivery methods
Time Frame: Week 4
Week 4

Secondary Outcome Measures

Outcome Measure
Time Frame
Injection pain intensity as assessed by a 0-10 numeric pain rating scale directly after the intradermal injection of NT 201 applied via different delivery methods in the forehead
Time Frame: Week 4
Week 4

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Merz Medical Expert, Merz Therapeutics GmbH

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 19, 2022

Primary Completion (Actual)

February 24, 2023

Study Completion (Actual)

April 13, 2023

Study Registration Dates

First Submitted

October 14, 2022

First Submitted That Met QC Criteria

October 14, 2022

First Posted (Actual)

October 18, 2022

Study Record Updates

Last Update Posted (Actual)

June 22, 2023

Last Update Submitted That Met QC Criteria

June 21, 2023

Last Verified

June 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe